Despite distinct clinical presentation and outcome, systemic, primary cutaneous, and breast implant-associated anaplastic large cell lymphomas (S-, PC-, BI-ALCL) ALK-negative (ALK−) show similar histopathological features including the presence of the “hallmark” cells with horseshoe-shaped nuclei and CD30 protein expression. The purpose was to better characterize these three entities using immunohistochemistry and FISH (Fluorescent in situ hybridization) to identify biomarkers differently expressed and that might be involved in their pathogenesis. Twenty-two S-ALCL ALK−, 13 PC-ALCL, and 2 BI-ALCL were included. Cases were tested for P53, P63, MUM1, MYC, GATA3, p-STAT3, PD1, and PDL1 protein expression and DUP22, TP53, TP63, MYC, and PDL1 chromosomal aberrations. As expected, S-ALCL ALK− patients had adverse outcome compare to PC and BI-ALCL. No difference was observed between the three groups concerning protein expression except for MUM1 that was significantly more frequently expressed in S-ALCL ALK− compared to PC-ALCL. In particular, constitutive activation of the STAT3 pathway and PDL1/PD1 immune-checkpoint expression was present in the three entities. TP53 deletion and PDL1 gene amplification were the commonest cytogenetic alterations and were present in the three entities. None of the studied biological parameters was associated with prognosis. Despite distinct clinical behavior, S-ALCL ALK−, PC-ALCL, and BI-ALCL share similar biological features. Larger series should be investigated with the current approach to determine more precisely the activity and the prognostic value of these biomarkers and pathways in each group.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Johnson NA, Slack GW, Savage KJ et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol Off J Am Soc Clin Oncol 30:3452–3459 Published Online First: 30 July 2012. https://doi.org/10.1200/JCO.2011.41.0985
Zhang W, Wang Z, Luo Y et al (2016) GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma. Oncotarget 7:65284–65294. https://doi.org/10.18632/oncotarget.11673
Chavan RN, Bridges AG, Knudson RA, Ketterling RP, Comfere N, Wada DA, Torres-Cabala C, DiCaudo DJ, Vasmatzis G, Pittelkow MR, Feldman AL (2014) Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course. Blood Cancer J 4:e253. https://doi.org/10.1038/bcj.2014.73
Chatzitolios A, Venizelos I, Tripsiannis G, Anastassopoulos G, Papadopoulos N (2010) Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin’s lymphoma. Ann Hematol 89:889–896. https://doi.org/10.1007/s00277-010-0945-x
Shukuya T, Carbone DP (2016) Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 11:976–988. Published Online First: 1 March 2016. https://doi.org/10.1016/j.jtho.2016.02.015
Krishnan C, Warnke RA, Arber DA, Natkunam Y (2010) PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. Am J Surg Pathol 34:178–189. https://doi.org/10.1097/PAS.0b013e3181cc7e79
van Dongen JJ, Langerak AW, Brüggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257–2317. https://doi.org/10.1038/sj.leu.2403202
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L (2016) Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol Off J Eur Soc Med Oncol ESMO 27:306–314. https://doi.org/10.1093/annonc/mdv575
ten Berge RL, de Bruin PC, Oudejans JJ, Ossenkoppele GJ, van der Valk P, Meijer CJLM (2003) ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 43:462–469
Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten W, Meijer CJ, Willemze R (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch cutaneous lymphoma group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653–3661
Booken N, Goerdt S, Klemke C-D (2012) Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG 10:331–339. https://doi.org/10.1111/j.1610-0387.2011.07794.x
Aladily TN, Medeiros LJ, Amin MB, Haideri N, Ye D, Azevedo SJ, Jorgensen JL, de Peralta-Venturina M, Mustafa EB, Young KH, You MJ, Fayad LE, Blenc AM, Miranda RN (2012) Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. Am J Surg Pathol 36:1000–1008. https://doi.org/10.1097/PAS.0b013e31825749b1
Aladily TN, Medeiros LJ, Alayed K, Miranda RN (2012) Breast implant-associated anaplastic large cell lymphoma: a newly recognized entity that needs further refinement of its definition. Leuk Lymphoma 53:749–750. https://doi.org/10.3109/10428194.2011.639020
Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA Jr, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT Jr, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ (2014) Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol Off J Am Soc Clin Oncol 32:114–120. https://doi.org/10.1200/JCO.2013.52.7911
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD, for the International Peripheral T-Cell Lymphoma Project (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood 111:5496–5504. https://doi.org/10.1182/blood-2008-01-134270
Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473–1480. https://doi.org/10.1182/blood-2014-04-571091
Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, Kurtin PJ, Dogan A (2009) Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leuk Off J Leuk Soc Am Leuk Res Fund UK 23:574–580. https://doi.org/10.1038/leu.2008.320
Heo MH, Park HY, Ko YH, Kim WS, Kim SJ (2017) IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer 8:1018–1024. https://doi.org/10.7150/jca.17358
Zinzani PL, Pellegrini C, Broccoli A et al (2011) Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma 52:1585–1588. https://doi.org/10.3109/10428194.2011.573031
Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, Glaisner S, Gabarre J, Bosly A, Lister J, Li J, Coiffier B (2013) A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer Oxf Engl 1990 49:2869–2876. https://doi.org/10.1016/j.ejca.2013.04.029
Pedersen MB, Hamilton-Dutoit SJ, Bendix K et al (2017) DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood 130:554–557. Published Online First: 18 May 2017. https://doi.org/10.1182/blood-2016-12-755496
Wang X, Boddicker RL, Dasari S, Sidhu JS, Kadin ME, Macon WR, Ansell SM, Ketterling RP, Rech KL, Feldman AL (2017) Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping. Hum Pathol 64:19–27. https://doi.org/10.1016/j.humpath.2017.01.003
Han JJ, O’byrne M, Stenson MJ, Maurer MJ, Wellik LE, Feldman AL, McPhail ED, Witzig TE, Gupta M (2018) Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. Blood Cancer J 8:110. https://doi.org/10.1038/s41408-018-0138-8
Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G, European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies” (2015) Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27:516–532. https://doi.org/10.1016/j.ccell.2015.03.006
Blombery P, Thompson E, Jones K et al (2016) Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast-implant associated anaplastic large cell lymphoma. Haematologica 101:e387–e390. Published Online First: 19 May 2016. https://doi.org/10.3324/haematol.2016.146118
Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA, Teh BT, Lim ST, Tan SY, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Tubbs RR, Ott G, Geissinger E, Gaulard P, Piccaluga PP, Pileri SA, Au WY, Nakamura S, Seto M, Berger F, de Leval L, Connors JM, Armitage J, Vose J, Chan WC, Staudt LM, for the Lymphoma Leukemia Molecular Profiling Project and the International Peripheral T-cell Lymphoma Project (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123:2915–2923. https://doi.org/10.1182/blood-2013-11-536359
Rassidakis GZ, Thomaides A, Wang S, Jiang Y, Fourtouna A, Lai R, Medeiros LJ (2005) p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia 19:1663–1669. https://doi.org/10.1038/sj.leu.2403840
Li HL, Huang XP, Zhou XH, Ji TH, Wu ZQ, Wang ZQ, Jiang HY, Liu FR, Zhao T (2011) Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, cytochrome C, and cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma. Biomed Environ Sci BES 24:630–641. https://doi.org/10.3967/0895-3988.2011.06.007
Jung JT, Kim DH, Kwak EK, Kim JG, Park TI, Sohn SK, Do YR, Kwon KY, Song HS, Park EH, Lee KB (2006) Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. Ann Hematol 85:575–581. https://doi.org/10.1007/s00277-006-0127-z
Weilemann A, Grau M, Erdmann T, Merkel O, Sobhiafshar U, Anagnostopoulos I, Hummel M, Siegert A, Hayford C, Madle H, Wollert-Wulf B, Fichtner I, Dörken B, Dirnhofer S, Mathas S, Janz M, Emre NCT, Rosenwald A, Ott G, Lenz P, Tzankov A, Lenz G (2015) Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma. Blood 125:124–132. https://doi.org/10.1182/blood-2014-08-594507
Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L, Albano EA, Quinones R, Cook B, Graham DK (2013) Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma. J Pediatr Hematol Oncol 35:e209–e213. https://doi.org/10.1097/MPH.0b013e3182815046
Monaco S, Tsao L, Murty VV, Nandula SV, Donovan V, Oesterheld J, Bhagat G, Alobeid B (2007) Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c-myc rearrangement terminating in a leukemic phase. Am J Hematol 82:59–64. https://doi.org/10.1002/ajh.20758
Wada DA, Law ME, Hsi ED, DiCaudo DJ, Ma L, Lim MS, Souza A, Comfere NI, Weenig RH, Macon WR, Erickson LA, Özsan N, Ansell SM, Dogan A, Feldman AL (2011) Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol Off J U S Can Acad Pathol Inc 24:596–605. https://doi.org/10.1038/modpathol.2010.225
Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, Vergier B, Jouary T, Beylot-Barry M, Merlio JP (2010) IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol 130:816–825. https://doi.org/10.1038/jid.2009.314
Huang H-S, Liao C-K, Liu T-T, You HL, Wang MC, Huang WT (2018) TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression. Hum Pathol 80:145–151. https://doi.org/10.1016/j.humpath.2018.05.026
Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, Macé A, Leventoux N, Costes V, Szablewski V (2016) Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch Int J Pathol 469:697–706. https://doi.org/10.1007/s00428-016-2016-8
Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C (2017) The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia 31:705–711. https://doi.org/10.1038/leu.2016.263
Stefancikova L, Moulis M, Fabian P et al (2011) Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Int J Oncol 39:1413–1420. https://doi.org/10.3892/ijo.2011.1170
Shi M, Roemer MGM, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ (2014) Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 38:1715–1723. https://doi.org/10.1097/PAS.0000000000000297
Mitteldorf C, Berisha A, Pfaltz MC, Broekaert SMC, Schön MP, Kerl K, Kempf W (2017) Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large B-cell lymphoma-new therapeutic targets. Am J Surg Pathol 41:998–1004. https://doi.org/10.1097/PAS.0000000000000851
Menguy S, Prochazkova-Carlotti M, Beylot-Barry M, Saltel F, Vergier B, Merlio JP, Pham-Ledard A (2017) PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type. Am J Surg Pathol 42:326–334 Published Online First: 3. https://doi.org/10.1097/PAS.0000000000000983
Four M, Cacheux V, Tempier A et al (2017) PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol 35:487–496. Published Online First: 13 December 2016. https://doi.org/10.1002/hon.2375
Twa DDW, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, Steidl C (2014) Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123:2062–2065. https://doi.org/10.1182/blood-2013-10-535443
Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869–881. https://doi.org/10.1182/blood-2015-10-673236
Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, Tanaka H, Chiba K, Ito S, Watatani Y, Kakiuchi N, Suzuki H, Yoshizato T, Yoshida K, Sanada M, Itonaga H, Imaizumi Y, Totoki Y, Munakata W, Nakamura H, Hama N, Shide K, Kubuki Y, Hidaka T, Kameda T, Masuda K, Minato N, Kashiwase K, Izutsu K, Takaori-Kondo A, Miyazaki Y, Takahashi S, Shibata T, Kawamoto H, Akatsuka Y, Shimoda K, Takeuchi K, Seya T, Miyano S, Ogawa S (2016) Aberrant PD-L1 expression through 3’-UTR disruption in multiple cancers. Nature 534:402–406. https://doi.org/10.1038/nature18294
Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ (2017) PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 31:1633–1637. https://doi.org/10.1038/leu.2017.103
Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107:1696–1704. https://doi.org/10.1111/cas.13065
Ma C, Horlad H, Pan C, Yano H, Ohnishi K, Fujiwara Y, Matsuoka M, Lee A, Niidome T, Yamanaka R, Takeya M, Komohara Y (2017) Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. J Clin Exp Hematop JCEH 57:21–25. https://doi.org/10.3960/jslrt.17006
Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T, Akashi K, Takayanagi R, Shiratsuchi M, Ohshima K (2015) Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood 126:2193–2201. https://doi.org/10.1182/blood-2015-02-629600
Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ (2016) PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 7:59976–59986. https://doi.org/10.18632/oncotarget.11045
This study was carried out in agreements with the Declaration of Helsinki and was approved by the Centre des Ressources Biologiques (CRB) of the Centre-Hospitalo-Universitaire (CHU) of Montpellier, France.
Written informed consent for the study was obtained from the patient.
Conflict of interest
The authors declare that they have no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
About this article
Cite this article
Gerbe, A., Alame, M., Dereure, O. et al. Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior. Virchows Arch 475, 163–174 (2019). https://doi.org/10.1007/s00428-019-02570-4
- Anaplastic lymphoma
- Breast implant